16.25
-1.44(-8.14%)
Currency In USD
| Previous Close | 17.69 |
| Open | 17.85 |
| Day High | 17.85 |
| Day Low | 16.25 |
| 52-Week High | 26.4 |
| 52-Week Low | 6.53 |
| Volume | 94,895 |
| Average Volume | 119,469 |
| Market Cap | 142.26M |
| PE | -2.39 |
| EPS | -6.79 |
| Moving Average 50 Days | 12.06 |
| Moving Average 200 Days | 13.36 |
| Change | -1.44 |
If you invested $1000 in Seres Therapeutics, Inc. (MCRB) 10 years ago, it would be worth $413.59 as of August 20, 2025 at a share price of $16.25. Whereas If you bought $1000 worth of Seres Therapeutics, Inc. (MCRB) shares 5 years ago, it would be worth $645.1 as of August 20, 2025 at a share price of $16.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
GlobeNewswire Inc.
Jul 22, 2025 11:01 AM GMT
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. E
Seres Therapeutics Announces Leadership Transition
GlobeNewswire Inc.
Jul 22, 2025 11:00 AM GMT
Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, includin
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
May 27, 2025 11:00 AM GMT
Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT)CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE